Do trade deals threaten India as low-cost HIV drug maker?

Friday, August 5, 2016

If there was one success story to emerge from the International AIDS Conference in Durban, South Africa, it was that more people are getting treated for HIV/AIDS than ever before — about 17 million by the latest United Nations estimate.

Falling drug prices played a key role in helping providers reach this point. But the international health group Doctors Without Borders (Médecins Sans Frontières) warned at a press conference that trade negotiations around the world put future gains at risk.

The group said its latest report “examines multiple global threats to access to affordable treatment, including trade deals which threaten India’s role as the ‘pharmacy of the developing world.’”

Trade is at the center of the U.S. presidential election for its effect on the American work force. But is there more at play? We wondered if it’s true that the next round of agreements, both those that involve the United States and those that don’t, would undermine some large drug makers in India.

Source: Politifact (link opens in a new window)

Health Care